MIAT and B-cell chronic lymphocytic leukemia: Upregulation of MIAT in aggressive forms of CLL and its biological activity in mature B cell malignancy indicate that MIAT may serve as a potential predictor for the disease outcome and its involvement in proliferation of the malignant B cells.